Speakers & Moderators
Fabio Ynoe de Moraes
Dr. Moraes is an Assistant Professor in the Department of Oncology at Queen’s University. He is a full time attending staff at Kingston General Hospital and Hotel Dieu Hospital and is an academic radiation oncologist. His research interests include global oncology, cancer health services research, cancer prognosis and outcomes, stereotactic techniques and technology development, and clinical trials.
Dr. Khader is a Consultant, Radiation Oncologist and Head of Genitourinary Radiation Oncology Services at the King Hussein Cancer Centre in Jordan.
Amanda CaissieMD FRCPC
Assistant Professor, Dalhousie University
Dr. Caissie is a radiation oncologist at the Saint John Regional Hospital and assistant professor in Dalhousie’s Department of Radiation Oncology. A native Maritimer, she returned to New Brunswick in 2012 after completing medical school at Queen’s University and radiation oncology residency at the University of Toronto. A McGill alumna who completed her PhD in 2005, Dr. Caissie’s current research interests focus on quality improvement (QI) in radiotherapy through inter-departmental/interdisciplinary collaboration. Her contributions to national radiotherapy QI initiatives include Steering Committee member of the Canadian Partnership for Quality Radiotherapy (CPQR) and Chair of the Canadian Association of Radiation Oncology (CARO) Quality and Standards Committee.
Allison Crawford is a psychiatrist and Associate Professor in the Department of Psychiatry, University of Toronto, where she is the Director of the Northern Psychiatric Outreach Program and Telepsychiatry at the Centre for Addiction and Mental Health.
Marzyeh Ghassemi is an Assistant Professor at the University of Toronto in Computer Science and Medicine, and a Vector Institute faculty member holding a Canadian CIFAR AI Chair and Canada Research Chair.
Melissa is a Junior Bioethicist with the Bioethics Department at The Hospital for Sick Children. She completed her PhD in Neuroscience at McMaster University and is completing her Master’s of Health Sciences in Bioethics at the University of Toronto. She was the inaugural postdoctoral fellow in Ethics of Artificial Intelligence and Healthcare, co-supervised by Anna Goldenberg and Randi Zlotnik Shaul. Melissa’s current work explores the ethical considerations of healthcare machine learning, artificial intelligence, and novel technologies in paediatric healthcare. She is a member of the CONSORT-AI and SPIRIT-AI Working Groups establishing reporting guidelines for clinical trials involving AI.
Ezra Hahn is a radiation oncologist, clinician-investigator, at Princess Margaret Cancer Centre and Assistant Professor in the Department of Radiation Oncology at the University of Toronto. He completed a specialized honours in mathematics at York University, following which he received his MD at the University of Toronto, where he also completed residency training. Subsequently, Ezra completed a clinical research fellowship at Princess Margaret Cancer Centre with a focus on head and neck malignancies. His academic interests center around predictive modeling and clinical research. Ezra's clinical interests are in prostate, testes, breast, and head and neck sarcoma cancers.
Irene Dankwa-Mullan MD MPH
Deputy Chief Health Officer
IBM Watson Health
Dr. Dankwa-Mullan is an industry scientist, physician-researcher with nearly two decades of experience in clinical research, public health, disparities and population health. She is currently Deputy Chief Health Officer at IBM Watson Health, Chief Health Equity Officer and lead scientific officer with the Center for AI, Research and Evaluation. She spent nearly a decade delivering and managing front-line primary care, preventive services, and community-based clinical research as a physician administrator and medical director. Prior to joining IBM, she was at the National Institutes of Health, where she served as Director, Office of Innovation and Program Coordination and then as Deputy Director for Division of Scientific Programs within the National Institute on Minority Health and Health Disparities. While at the NIH, she was an active member on several key strategic boards and committees, including many that were cross-sectoral and transdisciplinary. She was awarded the first NIH Directors award for exceptional contribution to advancing science of health disparities. She has lectured in clinical research, and mentored several early research investigators, supported numerous significant scientific contributions, and publications.
Dr. Dankwa-Mullan attended Barnard College, earned her MD from Dartmouth Geisel School of Medicine, and completed her Internal Medicine internship and residency at Johns Hopkins Bayview Medical Center. She also obtained a Master’s degree in Infectious Disease Epidemiology and Biostatistics from the Yale School of Public Health.
Kelly Lane is a Project Director at Techna who has provided strategic and project management leadership for the development and implementation of enterprise wide solutions and multi-jurisdictional IT initiatives for over 15 years at the University Health Network. Kelly has expertise with the Canadian health IT landscape from leading national multi-year projects in collaboration with organizations such as Canada Health Infoway and the Canadian Partnership Against Cancer. Recently, she has been involved with developing and implementing machine learning algorithms as part of a clinical decision support tool implemented in Grand Rapids, Michigan. Kelly is currently working closely with an international industry partner to manage the co-development of an Oncology Information System. This innovative co-development project brings together UHN clinicians, researchers and industry to define and build a next generation oncology system that can support all domains of cancer care including concurrent and adaptive therapies.
At UHN Kelly has led much of the initial work around electronic clinical documentation and her work on the development of the Electronic Medication Information Transfer Tool (EMITT) helped set the standard for medication reconciliation at a national and international level. Kelly’s projects have won several awards including the Best International Best Practice Award at the 2006 OHA convention for the University Health Network’s electronic Discharge Summary.
Chris McIntosh is a Scientist at the Techna Institute, the Peter Munk Cardiac Centre, and the Joint Department of Medical Imaging, at the University Health Network, an Assistant Professor in the Dept. of Medical Biophysics at the University of Toronto, and an Affiliate Faculty of the Vector Institute. Dr. McIntosh received the B.Sc. degree with honours in Computing Science from Simon Fraser University (SFU) in 2005 and his PhD in 2011 under the supervision of Dr. Ghassan Hamarneh. He is the recipient of academic awards from NSERC, CIHR, and the Michael Smith Foundation for Health Research. His dissertation received an honourable mention for the top dissertation in computer vision and medical image analysis by the Canadian Image Processing and Pattern Recognition Society. In 2010 he was a visiting researcher with the GALEN group at INRIA, Sacley, France, and Ecole Centrale de Paris. In 2012 he joined the Department of Radiation Physics as a Research Associate working in the labs of Drs. Tom Purdie and David Jaffray. In 2019 he started his own lab focusing on the theory and clinical application of AI in medicine for improving patient care including transfer learning, meta learning, computer vision, and explainable AI. Applications include deep learning for automated diagnosis, segmentation, quality assurance, and treatment planning. In particular, he and Tom Purdie’s work in radiation therapy has been commercialized and is now deployed in hospitals around the world, using AI to deliver reproducible, high quality cancer care.
Dr. Eichler was born and raised in Syracuse, NY, and received his Bachelor’s Degree in American Studies in 1974 from the University of Notre Dame. He attended medical school at the Virginia Commonwealth University’s Medical College of Virginia and received his MD in 1987. He did his internship in general surgery followed by post graduate training at the Massey Cancer Center in radiation oncology and was Board-certified in 1993. With the exception of a 3-year stint at the Louis Busch Hager Cancer Center in Cooperstown, NY, Dr. Eichler has spent his entire career in central Virginia and retired from full-time practice in 2017 after 16 years at the Sarah Cannon Cancer Institute at Johnston-Willis Hospital in Richmond. He is currently on staff at VCU Health’s Massey Cancer Center.
He has been active in the American Society for Radiation Oncology or ASTRO, the largest radiation oncology professional society in the world, for over 25 years, was accorded Fellowship in 2013 and was elected President in 2018. He is active in a number of local, national and international cancer-related organizations as well as performing volunteer work in the community. He has been seen in multiple Richmond-area stage productions over the past 12 years and remains an avid reader and ardent sports fan. He is a man of many interests with an insatiably curious mind.
Avi Goldfarb is the Rotman Chair in Artificial Intelligence and Healthcare, and Professor of Marketing at Rotman. Avi is also Chief Data Scientist at the Creative Destruction Lab, Senior Editor at Marketing Science, and a Research Associate at the National Bureau of Economic Research. His research on the economics of technology has been discussed in White House reports, Congressional testimony, European Commission documents, the Economist, the Globe and Mail, the National Post, CBC Radio, National Public Radio, Forbes, the Atlantic, the New York Times, the Financial Times, the Wall Street Journal, and elsewhere. Along with Ajay Agrawal and Joshua Gans, Avi is the author of the Globe & Mail bestselling book Prediction Machines: The Simple Economics of Artificial Intelligence.
Gary Rodin is the University of Toronto/University Health Network Chair in Psychosocial Oncology and Palliative Care and Head of the Department of Supportive Care at Princess Margaret Cancer Centre in Toronto, Canada. Dr. Rodin is also the Director of the Global Institute of Psychosocial, Palliative and End-of-Life Care (GIPPEC) and a Professor of Psychiatry at the University of Toronto. He leads a clinical and research program on the psychosocial dimensions of advanced and terminal disease and on the development and evaluation of novel interventions to improve the quality of life and the quality of dying and death in this population. These integrated psychosocial and palliative interventions include Managing Cancer and Living Meaningfully (CALM), a supportive-expressive psychotherapeutic treatment for patients with metastatic cancer and their caregivers, and an integrated emotion and symptom-focused intervention for individuals diagnosed with life-threatening hematological malignancies of acute onset. Through GIPPEC, a University of Toronto Interdisciplinary Institute based at Princess Margaret, Dr. Rodin has established international partnerships in Europe, Asia, Africa, Australia and the Middle East to contribute to global access to palliative and supportive care for patients and families facing advanced disease and the end of life. He has published widely in these areas and is recognized internationally for his efforts to improve the rigor of research and the effectiveness and availability of psychosocial and palliative interventions.
David Jaffray is senior vice president and chief technology and digital officer at The University of Texas MD Anderson Cancer Center. He also is professor of Radiation Physics with a dual appointment as professor of Imaging Physics.
Recruited to MD Anderson in May 2019, Dr. Jaffray is the institution’s first-ever chief technology and digital officer, bringing more than two decades of scientific expertise and proven skill as an innovator. In his new role, he will direct the strategic design, acquisition, management and implementation of an enterprise-wide technology infrastructure at MD Anderson to safeguard the integrity and availability of the institution’s systems and intellectual property assets. While overseeing the Information Services division and Information Security department, Dr. Jaffray will lead efforts to advance data integration, data governance and data security across MD Anderson’s Houston campuses and its national network, as well as coordinate technology-enabled innovation. Additionally, he will collaborate with the Strategic Industry Ventures team and the chief scientific officer in advancing meaningful partnerships with industry.
Before joining MD Anderson, Dr. Jaffray served as executive vice president for Technology and Innovation at the University Health Network (UHN)/Princess Margaret Cancer Centre in Toronto, Ontario. He led UHN’s information technology transformation, designed the roadmap for digital transformation and initiated the procurement process for UHN’s health information system. He also served in several other leadership roles at UHN, including vice chair of Radiation Oncology, founding director of Preclinical and Computational Cores for the STTARR Innovation Centre, and director of the Techna Institute for the Advancement of Technology for Health.
Dr. Jaffray has an interest in commercialization and has led the development of a variety of commercial products, including software and hardware for safe, high-quality cancer care and the development of small-animal irradiator systems for basic research. He holds multiple patents and has authored more than 275 peer-reviewed publications. During the course of his career, he has received many honors, including the Sylvia Sorkin-Greenfield Award, the Farrington Daniels Award and the Sylvia Fedoruk Award. In 2018, he received the Gold Medal from the American Society for Radiation Oncology.
Dr. Jaffray earned his bachelor’s in physics from the University of Alberta, and his doctorate in medical biophysics from the University of Western Ontario in London, Ontario.
Sabelo is a computer scientist and researcher whose work focuses on the ethical implications of technology in the developing world, particularly in Sub-Saharan Africa, along with the creation of tools to make Artificial Intelligence more accessible and inclusive to underrepresented communities.
His research centers on examining the risks and opportunities of AI in the developing world, and in the use of indigenous ethical models as a framework for creating a more humane and equitable internet. His current technical projects include the creation of Natural Language Processing models for African languages, alternative design of web-platforms for decentralizing data and an open-source library for offline networks.
During his Fellowship he will conduct research on Ethics & Technology and extend his work on Artificial Intelligence for the Developing World.
As Vice President, Health Strategy and Partnerships, Alison Paprica is the Vector Institute’s corporate lead for health strategy, overseeing health research collaborations, health data partnerships and health AI application projects. Prior to joining Vector in November 2017, Alison's roles included: Director, Strategic Partnerships at the Institute for Clinical Evaluative Sciences (ICES), Director of the Planning, Research & Analysis Branch at the Ontario Ministry of Health & Long-Term Care and Manager of Performance Measurement & Results at the Ontario Ministry of Research & Innovation. From 1993-2001 she worked in international pharmaceutical R&D at Eli Lilly, Astra Pharma and Genpharm Inc. Alison holds an Honours Combined BSc in Biochemistry and Chemistry (McMaster), a PhD in organic chemistry (Western University) and is Assistant Professor (status) at IHPME. She is among the first 5% of people to obtain Project Management Professional (PMP) certification internationally, and developed and delivers courses and workshops at the University of Toronto focused on leadership and management of research.
Rifat Atun is Professor of Global Health Systems at Harvard University, and the Director of Global Health Systems Cluster at Harvard T.H. Chan School of Public Health.
Professor Atun’s research focuses on the design and implementation of health systems reforms and their impact on outcomes. His research also explores adoption and diffusion of innovations in health systems (e.g. health technologies, disease control programmes, and primary healthcare reforms), and innovative financing in global health. Prof. Atun is a co-Investigator and the joint lead for the innovation work stream at the National Centre for Infection Prevention and Management at Imperial College. He is also a co-Investigator and the Theme Lead for ‘Organisational Change, Sustainability and Evaluation’ at Imperial College and Cambridge University Health Protection Research Unit for Antimicrobial Resistance and Healthcare Associated Infection. He has published widely in the Lancet, PLoS Medicine, Lancet Infectious Diseases, BMJ, AIDS, and Bulletin of the World Health Organization.
Prof. Atun has worked with several governments globally as well as the World Bank, World Health Organization, and the UK Department for International Development to design, implement and evaluate health system reform initiatives. He has led research and consultancy projects for GSK, Pfizer Inc., the Vodafone Group, Hofmann La Roche, PA Consulting, and Tata Consulting Services.
Prof. Atun studied medicine at University of London as a Commonwealth Scholar and subsequently completed his postgraduate medical studies and Masters in business administration at University of London and Imperial College London. He is a Fellow of the Royal College of General Practitioners (UK), Fellow of the Faculty of Public Health of the Royal College of Physicians (UK), and a Fellow of the Royal College of Physicians (UK).
Yolande Lievens is the chair of the Radiation Oncology department of the Ghent University Hospital in Belgium and Professor in Radiation Oncology at the Ghent University. She graduated in Medicine at the Leuven University in 1991, and specialised in Radiation Oncology. In 2002 she completed her PhD program, focusing her research on Cost and Economic evaluation of Radiotherapy.
Yolande is the President of ESTRO (European Society for Radiotherapy and Oncology) and the co-chair of the HERO project (Health Economics in Radiation Oncology), whose overall aim is to develop a knowledge base and a model for health economic evaluation of radiation treatments at the European level. She collaborates with international organisations such as the IAEA, CCORE and UICC, she was a member of the Global Task Force in Radiotherapy on Cancer Control (GTFRCC) and co-author on the Lancet Oncology Commission. And at national level, she collaborates with the Belgian Health Care Knowledge Centre and the Belgian Cancer Registry.
Dr Ajay Aggarwal is a Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Trust, London (UK). He is an Associate Professor at the London School of Hygiene and Tropical Medicine with honorary senior lectureships at King’s College London and the MRC Clinical Trials Unit at University College London. His main research areas are health services research, clinical epidemiology and global health and he is the current editor of the Journal of Cancer Policy.
Since 2013, he has been the Oncology Coordinator for the National Prostate Cancer Audit, based at the Royal College of Surgeons of England. As part of this work, he developed the first-ever national radiotherapy outcomes public reporting program for all patients receiving prostate cancer radiotherapy in the English NHS. He has previously undertaken innovative research using quantitative and qualitative methods to demonstrate how patient choice and hospital competition are key drivers in the adoption of high cost, low value surgical devices for cancer treatment.
He has worked at the World Health Organisation in Geneva and has ongoing projects in Ghana, Botswana, Zambia and Tanzania aimed at building radiotherapy capacity and research capability. He was recently awarded, in collaboration with the MD Anderson Cancer Centre, USA, and Stellenbosch University, South Africa, a Wellcome Trust Digital Innovator Award, to use Artificial Intelligence to automate radiotherapy treatment planning for the treatment of urgent and emergency presentations of advanced cancers.
Danielle Rodin, MD, MPH, FRCPC, is a radiation oncologist at Princess Margaret Cancer Centre and an Assistant Professor in the Department of Radiation Oncology at the University of Toronto. She was the 2017-2018 Canadian Harkness Fellow in Health Care Policy and Practice in the Department of Health Policy and Management at the Harvard T. H. Chan School of Public Health and has published more than 40 peer-reviewed papers in the areas of health technology assessment, global health systems, and large database analyses of cost and quality in cancer care. Rodin also recently worked as a Consultant in the Division of Human Health at the International Atomic Energy Agency, where she focused on the implementation and sustainability of radiotherapy programs in low-resource settings. She has been actively involved in the UICC, having twice received the Young Leader Award and has led successful advocacy movements using for improving access to cancer treatment using films, blogs, and other multimedia. Rodin received her B.A.(Hons.) from McGill University, her medical degree from the University of Toronto, and her Master of Public Health from Harvard University.
Benjamin Haibe-Kains is Scientist at the Princess Margaret Cancer Centre (PM), University Health Network, and Assistant Professor in the Medical Biophysics and Computer Science departments of the University of Toronto. Dr. Haibe-Kains earned his PhD in Bioinformatics at the Université Libre de Bruxelles (Belgium), for which he was awarded a Solvay Award (Belgium). Supported by a Fulbright Award, Dr. Haibe-Kains did his postdoctoral fellowship at the Dana-farber Cancer Institute and Harvard School of Public Health (USA). Dr. Haibe-Kains started his own laboratory at the Institut de Recherches Cliniques de Montréal (Canada) and moved to PM in November 2013. Dr. Haibe-Kains’ research focuses on the integration of high-throughput data from various sources to simultaneously analyze multiple facets of carcinogenesis. Dr. Haibe-Kains and his team are analyzing high-throughput (pharmaco)genomic datasets to develop new prognostic and predictive models and to discover new therapeutic regimens in order to significantly improve disease management. Dr. Haibe-Kains' main scientific contributions include several prognostic gene signatures in breast cancer, subtype classification models for ovarian and breast cancers, as well as genomic predictors of drug response in cancer cell lines.
Alejandro (Ale) Berlin
Alejandro (Ale) Berlin obtained his Medical Degree as valedictorian from the Pontifical Catholic University of Chile. He underwent radiation oncology specialty training in Chile, Israel and Canada, which included a clinical-research fellowship and a MSc degree in genitourinary translational oncology at the University of Toronto. Currently, he is a staff clinician-scientist radiation oncologist at the Princess Margaret Cancer Centre (Toronto, Canada). His clinical practice focuses in the characterization of genitourinary malignancies with molecular and MR imaging, and novel applications of curative treatments combining systemic, stereotactic radiotherapy and MR-guided brachytherapy approaches. He is particularly interested in the design of innovative clinical trials, translational oncology, and the discovery of biomarkers using high-throughput genomics. Dr. Berlin leads the clinical deployment of novel technologies such as AI-based radiotherapy planning methods for prostate cancer, and TECHNA’s development and application of technology to enable the routine collection of outcomes at the point of care. At this early stage of his career Ale aims to convey his clinical and research expertise towards improving and individualizing the treatments for patients with prostate cancer.
Meredith Giuliani is an associate professor in the University of Toronto, Department of Radiation Oncology and a radiation oncologist at the Princess Margaret Cancer Centre. She received her MBBS qualification from the University of London, England and her Master’s of Education from the University of Toronto. She completed her residency training at the University of Toronto. She is the Medical Director of Education for Princess Margaret Cancer Centre and the Cancer Care Ontario Smoking Cessation Champion for Toronto Central South. Her clinical interests are in lung and head and neck cancers.
Stephanie Sliekers, MEd, is the Manager, Simulation and Digital Innovation at Canada's largest mental health teaching hospital, the Centre for Addiction and Mental Health (CAMH). She is an educator with extensive experience leading the successful launch, implementation, and evaluation of countless continuing education and knowledge exchange projects. She brings to her work expertise in adult learning, implementation science, and digital communications. In her current role at CAMH, she manages Canada’s first Simulation Centre dedicated to training health professionals in mental health. She oversees CAMH Education’s digital innovation team, who are uniquely positioned to develop and disseminate digital mental health education products, including online courses and toolkits and mobile apps. Stephanie is a survivor of non-Hodgkin’s lymphoma. She recorded her journey as a young adult recovering from chemotherapy and radiation treatment online at www.100resolutions.com.
Thomas Purdie graduated from McMaster University, Hamilton, Ontario, Canada with a B.Sc. (Hons.) in the Medical and Health Physics program of the Department of Physics and Astronomy in 1997. He then completed his Ph.D. in the Department of Medical Biophysics at the University of Western Ontario in London, Ontario, Canada in 2002. Following graduate school, he completed a medical physics residency and research fellowship at Princess Margaret Cancer Centre (Toronto, Ontario Canada) in 2005. He is currently as Staff Physicist in the Radiation Medicine Program at Princess Margaret Cancer Centre. Dr. Purdie became a Board Certified Medical Physicist (CCPM – Radiation Therapy Physics) in 2007.
Dr. Purdie’s research focuses on developing automated methods for breast intensity modulated radiation therapy (IMR) treatment planning, implementing breast radiation therapy on multi-modal imaging platforms and using machine learning for improving radiation therapy quality assurance (QA) processes.
Ann Heesters is the Director of Bioethics at the University Health Network and a member of the University of Toronto’s Joint Centre for Bioethics. Ann has practiced in the field for more than 17 years and established the ethics services at Atlantic Health Sciences Corporation (now part of New Brunswick’s Horizon Health Network) and The Ottawa Hospital. She came to Toronto in 2009 to become Director of Ethics and Spiritual Care at the Toronto Rehabilitation Institute. Ann has an abiding interest professionalizing the work of health care ethicists and was a founding member of PHEEP (Practicing Healthcare Ethicists Exploring Professionalization) and an early director of CAPHE-ACCESS (the Canadian Association of Practicing Healthcare Ethicists). Ann is a former Research Ethics Board chair and her current interests include exploring ethics processes for the evaluation of research and quality improvement initiatives. She is now sitting on her institution’s relationship management committee and is helping that group to establish standards for managing conflict of interest cases.
Ann is a student of Philosophy and generally endorses Ronald Dworkin’s view that "Absolute confidence or clarity is the privilege of fools and fanatics."
Dr. David Wiljer is a member of the community providing groundbreaking perspectives and inspiring contributions to digital health policy, management, education and evaluation. He is the Executive Director of Education, Technology & Innovation at the University Health Network, and former Senior Director of Transformational Education and Academic Advancement at CAMH. David is also an Associate Professor in the Department of Psychiatry, Faculty of Medicine and the Institute of Health Policy Management and Evaluation at the University of Toronto. He is a former President of the American Association of Cancer Education, and was the founding Chair of a national working group, the Canadian Committee for Patient Accessible Electronic Health Records (CCPAEHR), dedicated to involving patients in their EH. He was also an inaugural Associate Director of the Centre for Health, Wellness and Cancer Survivorship at the Princess Margaret Cancer Program at the University Health Network.
His work focuses on patient and health professions education, specifically patient involvement, digitally enabled education and life-long learning. He has explored the development of large programs, infrastructure, communities, and research initiatives that involve health professionals, patients and families in new approaches to education and care delivery, including patient portals for providing patients with access to their health records and social networking approaches to promote self-management and self-care.
Rich Caruana is a senior principal researcher at Microsoft Research. Before joining Microsoft, Rich was on the faculty in the Computer Science Department at Cornell University, at UCLA’s Medical School, and at CMU’s Center for Learning and Discovery. Rich’s Ph.D. is from Carnegie Mellon University, where he worked with Tom Mitchell and Herb Simon. His thesis on Multi-Task Learning helped create interest in a new subfield of machine learning called Transfer Learning. Rich received an NSF CAREER Award in 2004 (for Meta Clustering), best paper awards in 2005 (with Alex Niculescu-Mizil), 2007 (with Daria Sorokina), and 2014 (with Todd Kulesza, Saleema Amershi, Danyel Fisher, and Denis Charles), co-chaired KDD in 2007 (with Xindong Wu), and serves as area chair for NIPS, ICML, and KDD. His current research focus is on learning for medical decision making, transparent modeling, deep learning, and computational ecology.
Dr. Fabrice Jotterand is Associate Professor of Bioethics and Medical Humanities and Director of the Graduate Program in Bioethics at the Center for Bioethics and Medical Humanities, Medical College of Wisconsin. He holds a second appointment as Senior Researcher at the Institute for Biomedical Ethics at the University of Basel. His scholarship and research interests focus on issues including neuroethics, ethical issues in psychiatry and mental health, the use of neurotechnologies in psychiatry, medical professionalism, neurotechnologies and human identity, and moral/political philosophy. He has published more than 50 articles and book chapters and five edited books. His present research focuses on an examination of the ethical, regulatory and social issues arising from the use of emerging neurotechnologies (including AI) in psychiatry and neurology. He is working on a book, entitled The Unfit Brain and the Limits of Moral Bioenhancement, that focuses on the ethical and social implications of the potential use of neurotechnologies in psychiatry to alter brain functions to address so-called “moral pathologies” (antisocial, aggressive, and harmful behavior; psychopathic traits). He is also involved in the research project called REDIRECT (Research in Early Child Development to Improve Resiliency and Equity) that addresses questions of health disparities.
Ben Brzezynski is the Director of Business Development Operations with Enlitic, a medical artificial intelligence company based in San Francisco, California. Enlitic's mission is to improve the accuracy and efficiency of medical diagnostics through the use of deep learning and natural language processing technology. Primarily active in radiology, Enlitic develops medical device and business intelligence solutions that provide diverse value for medical imaging and population health management. Ben helps lead Enlitic's partnership and sales strategy globally and has facilitated research, co-development and deployment projects with hospitals and health systems in the United States, Canada, Australia, United Kingdom, Japan, Turkey, United Arab Emirates and India. Prior to Enlitic, Ben represented medical professions in financial and funding negotiations with payors and governments, and worked in corporate services at a large healthcare provider.
Luke Brzozowski leads TECHNA’s Technology Team, the Research Office of the Joint Department of Medical Imaging, and the UHN Oncology Biobank. His team comprises over eighty technical project managers, engineers, software developers, clinical trial coordinators, research pathology support personnel, as well as operational, quality, regulatory, marketing, and financial professionals who lead, manage, and carry out health technology productization programs and projects in a hospital environment. Prior to joining Techna at its inception (then as Director of Operations and Engineering), Luke held management positions in the development, marketing, legal, and regulatory departments in the health technology industry and pharmaceutical CRO. Luke is the recipient of the 2003 Governors General’s Gold Medal for his Doctorate from the Department of Electrical and Computer Engineering at the University of Toronto.
Michael Brudno is the Director of the Centre for Computational Medicine at SickKids Hospital and Professor in the Department of Computer Science (CS) at the University of Toronto. Michael’s main research interest is in the development of computational methods for the analysis of clinical and genomic datasets, especially the capture of precise clinical data from clinicians using effective user interfaces, and its utilization in the automated analysis of genomes. He is also leading HPC4Health, a joint project of SickKids and UHN to build a private computing cloud for Toronto hospitals.
After receiving a BA in CS and History from UC Berkeley, Michael received his PhD from CS Department of Stanford University, working on algorithms for whole genome alignments. He completed a postdoctoral fellowship at UC Berkeley and was a Visiting Scientist at MIT. He is the recipient of the Ontario Early Researcher Award and the Sloan Fellowship, as well as the Outstanding Young Canadian Computer Scientist Award.
Gillian Strudwick RN, PhD is a Registered Nurse and Scientist at the Centre for Addiction and Mental Health in Toronto. She is an Assistant Professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto and President of the Ontario Nursing Informatics Group. Her work in cancer care has consisted of clinical work in surgical oncology at Mount Sinai Hospital, and at UHN International at Kuwait Cancer Control Center.
Duoaud has been a part of the TECHNA team since 2012, initially as a project manager in addition to managing operations at the UHN Microfabrication Centre. In his current role as Manager – Consulting Services and Co-Development, he is responsible for engaging with both internal and external teams to realize co-development opportunities for mature health technologies spanning health IT to medical devices. He is currently working with JDMI (Joint Department of Medical Imaging – UHN/MSH/WCH) AI Centre to establish processes for enabling internal AI research and partnerships with industry. On the consulting side, he leads a team in providing consulting services in quality (ISO 13485, 9001, 27799 etc.), regulatory (Health Canada, FDA), software development and engineering to both internal and external clients. Prior to TECHNA, Duoaud was responsible for research and development in a small medical device company with additional roles in quality and regulatory management. He holds an Hons. BSc. in Applied Physics from York University and an MSc. in Medical Biophysics from the University of Toronto.
Dr. Erin Watson graduated from the Faculty of Dentistry at McGill University in 2012 with the gold medal and subsequently completed a hospital-based dental residency at Mount Sinai hospital in 2013.
In 2014, she joined the staff at Princess Margaret Cancer Centre where she is now the Deputy Chief of Dentistry and co-director of the dental oncology fellowship program. As a clinician investigator, Dr. Watson has a special interest in the dental management of patients with acute leukemia and head and neck cancer. Highly involved in the administrative side of hospital-based dentistry, she sits on the Princess Margaret Cancer Centre patient experience committee, the Young Leaders advisory board and the cancer education advisory committee . She is also a board member of the Canadian Association of Hospital Dentists and a member of the Health Facilities Committee for the Commission on Dental Accreditation of Canada.
Dr. Watson provides continuing education lectures on the topic of dental care for cancer patients, both to dental study clubs and on behalf of the University of Toronto, where she holds an appointment as an Associate in Dentistry. She is also a guest lecturer at McGill University.
Head of Personalized Healthcare, Hoffmann-La Roche
Michael is the Head of Personalized Healthcare for Hoffmann-La Roche Limited. In this role, Michael leads a team responsible for Roche’s strategy to advance the personalization of healthcare in Canada. Michael is also a founding board of the Canadian Personalized Healthcare Innovation Network (CPHIN) which is a not for profit consortium of members from both public and private sectors focused on the acceleration of personalized healthcare for Canada.
Michael received his undergraduate degree in Biology and Pharmacology and a Ph.D. in Medical Sciences with a specialization in Neuroscience, both from McMaster University.
Mary Gospodarowicz is a University Professor at the University of Toronto, Medical Director of the Princess Margaret Cancer Centre, and Regional Vice President, Ontario Health/Cancer Care Ontario. She is past Chair of the Department of Radiation Oncology at the University of Toronto and Past-President of the Union for International Cancer Control (UICC). She is currently a member of the Board of Directors of the City Cancer Challenge 2025.
Nazik Hammad, Director of Global Health at the Faculty of Health Sciences, Queen's University, is an Associate Professor and medical oncologist in the Department of Oncology at Queen's. Dr. Hammad's interests include research and policy in medical education in particular health professions education in Low-and middle-income countries, in addition to health equity and value in cancer care. She served in the executive council of the African Organization for Research and Training in Cancer (AORTIC) 2015 to 2019
Dr. Maria Athina (Tina) Martimianakis
Dr. Maria Athina (Tina) Martimianakis is Associate Professor and Director of Medical Education Scholarship in the Department of Paediatrics, and Scientist and Associate Director Collaborations and Partnerships at the Wilson Centre, University of Toronto. Tina studies the socio-politics of education with a particular focus on issues related to the hidden curriculum, identity and faculty and learner experiences. Currently she is researching how organizational practices associated with discourses of collaboration support or hinder the capacity of interprofessional teams to practice and learn together.
February 20-21, 2020
Courtyard Toronto Downtown
475 Yonge Street
Toronto, ON M4Y 1X7
416-597-3422 ex 3448